Andreas Norlin
Chief Tech/Sci/R&D Officer bei ASCELIA PHARMA AB
Vermögen: 10 650 $ am 31.03.2024
Profil
Andreas L.
Norlin is the founder of Xkout Bioscience AB.
He is currently the Director at ApoGlyx AB and the Chief Scientific Officer at Ascelia Pharma AB.
Dr. Norlin has a graduate and doctorate degree from the University of Lund.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ASCELIA PHARMA AB
0,04% | 13.07.2023 | 12 364 ( 0,04% ) | 10 650 $ | 31.03.2024 |
Aktive Positionen von Andreas Norlin
| Unternehmen | Position | Beginn |
|---|---|---|
| ASCELIA PHARMA AB | Chief Tech/Sci/R&D Officer | 01.01.2020 |
ApoGlyx AB
 ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Director/Board Member | - |
Ehemalige bekannte Positionen von Andreas Norlin
| Unternehmen | Position | Ende |
|---|---|---|
| Xkout Bioscience AB | Founder | - |
Ausbildung von Andreas Norlin
| University of Lund | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ASCELIA PHARMA AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ApoGlyx AB
ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Health Technology |
| Xkout Bioscience AB |
